Biotech Dealmaking - Regulatory Considerations for the Next Wave of Development-Stage Transactions - Program and Lunch
2026-01-12 11:30 - 14:30 (America/Los_Angeles)
Join members of Sidley’s Global Life Sciences team for a lunchtime CLE-accredited program during the JPM Healthcare Conference discussing the latest regulatory trends impacting the next wave of development-stage transactions.

Led by Meena Datta, global co-leader of Sidley’s Healthcare practice; Torrey Cope, partner in Sidley’s Food Drug and Medical Device (FDMD) practice; and Sally Wagner Partin, partner in Sidley’s M&A practice, this session provides keen insights on the considerations driving recent biotech dealmaking. 1 hour CLE credit available.
For questions, please contact sfevents@sidley.com.

Connecting Clusters of Excellence: Europe as Your Gateway to Global Success
2026-01-12 13:30 - 17:30 (America/Los_Angeles) | The Town Hall, 555 California Street, San Francisco, CA, 94104, United States
Join Sidley, Biovia, Health Campus Limburg DC, and others for an engaging afternoon exploring collaborative growth opportunities across the global life sciences landscape.

RSVP here.
The event will feature two dynamic panel discussions, with the latter being moderated by Sidley’s Becky Wood, global co-leader of Sidley’s FDA practice and former Chief Counsel at FDA.
Panel 1: Europe Recharged: Innovation Thrives Here. We Are Ready for the Global Stage.
Europe’s biotech and healthtech ecosystems are accelerating. With strong public-private partnerships, world-class research, and coordinated investment strategies, Europe is no longer catching up, it’s setting the pace. Discover how clusters across the continent are shaping global markets through collaboration and scale.
Panel 2: Redefining Women’s Health: Europe and the U.S. Unite to Power Innovation, Investment, and Impact.
A new wave of investors and innovators is turning women’s health into one of the fastest-growing markets in healthcare. How can we ensure women’s health is not just a “hot topic,” but an enduring pillar of innovation and research? This panel brings together U.S. and European leaders driving science, technology, and capital toward an overdue revolution in women’s health, from overlooked needs to global opportunities.
This gathering brings together leaders, innovators, and ecosystem builders to spark meaningful dialogue and foster new pathways for international collaboration.
Please note that delegate contact details may be passed between Sidley Austin LLP, Biovia, and Health Campus Limburg DC for the purposes of organizing and administering these events, and for contacting you about these events. The organizers are using third party websites, not controlled by Sidley, and your personal information will be processed in accordance with the Eventbrite Privacy Policy. For information on Sidley’s use of your personal information please refer to our Privacy Policy and for questions about these events please contact sfevents@sidley.com.

At the Table: Serving Up a Lively Discussion With the FDA and USDA
2026-01-28 09:30 - 16:30 (America/New_York) | Sidley, 1501 K Street, NW Washington, D.C., 20005, United States
Please join Sidley’s Food, Drug, and Medical Device team for a Meet the Regulators Roundtable which will include: Stephen A. Vaden, USDA Deputy Secretary; Tyler Clarkson, USDA General Counsel; Kyle Diamantas, FDA Deputy Commissioner for Human Foods, and Sean Keveney, FDA Chief Counsel.

For registration information, please contact dcevents@sidley.com.

Agenda
Registration | 9:30 a.m. ET
Panels | 10:00 a.m. – 12:10 p.m. ET
Lunch | 12:15 p.m. – 1:15 p.m. ET
Meet the Regulators Roundtable | 1:30 p.m. – 3:00 p.m. ET
Cocktail Reception | 3:00 p.m. – 4:30 p.m. ET
The event will bring together industry leaders for a lively discussion on regulatory compliance, enforcement actions, litigation, and related issues facing the food industry.
Panel discussions prior to the Regulator Roundtable will include:
– The Changing Landscape in Washington Food Regulation
– Enforcement and Litigation – Risks, Opportunities, and Trends
CLE credit is pending for this program. Sidley Austin LLP is an Approved Accredited Provider of CA, IL, and NY CLE credit.

Life Sciences College 2026
2026-02-12 08:30 - 17:00 (Europe/Brussels) | Renaissance Brussels Hotel, Rue du Parnasse 19, Brussels, 1000, Belgium
Join EUCOPE and Sidley for the annual Life Sciences College (LSC) for an exclusive, full-day forum on the future of life sciences in Europe.

RSVP here.
Get ready for a high-impact day of insight and connection at LSC, where life sciences leaders gather to explore the legal, regulatory, and policy shifts shaping the industry.
Why Attend?

– Connect with key decision-makers from the European Commission, regulatory bodies, industry, and the investment community
– Hear exclusive insights on legal, policy, and regulatory trends shaping the EU life sciences landscape
– Join strategic discussions on emerging challenges and opportunities across the sector
– Network with leaders from pharma, biotech, medtech, and venture capital
Who Should Attend
In-house counsel, regulators, and regulatory personnel.There is no registration fee to attend this event.
For more information, contact brevents@sidley.com.

Sidley Sponsors the 2026 EU Pharma Law Forum
2026-05-19 - 2026-05-21 | Steigenberger Icon Wiltcher’s, Brussels
Sidley is proud to sponsor and participate in the EU Pharma Law Forum, the leading annual gathering of regulators, in-house counsel, policymakers, and industry stakeholders shaping the future of European pharmaceutical law.
View agenda here.
Sidley partner Anne Robert will be speaking on “How to Respond to Dawn Raids and Investigations.” Josefine Sommer will present on “Early Experiences from the HTA Regulation: Market Access Pricing and Reimbursement.”
We look forward to connecting with clients, colleagues, and industry leaders in Brussels to discuss the evolving legal landscape and the strategic considerations facing the pharmaceutical sector in 2026 and beyond.

Women’s Life Sciences Network – Biotech Act: Funding and Investment Opportunities
2026-05-19 17:30 - 21:00 (Europe/Brussels) | Comet, Place Stephanie 50, Brussels, 1050, Belgium
Join us in Brussels for our next Women’s Life Sciences Network event on the occasion of the EU Pharmaceutical Law Forum.

RSVP here.

Our speakers will discuss the proposed Biotech Act I, focusing on funding and regulatory support opportunities for the European biopharmaceutical industry.
Join our moderated panel discussion with:
Felicitas Riedl, Director of Innovation and Competitiveness Department, European Investment Bank
Alexandra Eftimie, Legal and Policy Officer, European Commission
Kristin Thompson, Director, Merieux Equity Partner
Valerie Vanhooren, CEO & Co-founder, Ona Therapeutics
The event will include a video address by Stine Bosse, MEP for the Renew Europe group and Vice Chair of the Committee on Public Health in the European Parliament.
Agenda
Welcome and registration – 5:30 p.m. CEST
Panel discussion and Q&A – 6:00 p.m. CEST
Networking reception and canapés – 7:30 p.m. CEST
Stay tuned for more details. All are invited to attend WLSN events.

Boston Life Sciences RoundtableThe Next Phase: Capital Strategy & Regulatory Alignment
2026-06-09 13:30 - 18:30 (America/Chicago) | Boston, MA
Join Sidley’s Life Sciences team for an afternoon of thought-provoking and engaging discussions touching on the latest trends and hot topics including the current administration, emerging technologies, the investment landscape, and more.

Featured Panel Topics
Pipelines and Product Launches: The New Normal for Strategic FDA and Pricing Planning
This panel will explore regulatory issues impacting activities critical to successful product launches and exits today, including regulatory approval, disease awareness and other pre-approval communications, reimbursement planning in the era of MFN policy considerations, relationships with investigators, and continued access for clinical trial patients following product approval but before formulary access.
– Torrey Cope, Partner, Food, Drug and Medical Device
– Meena Datta, Partner, Global Co-leader, Healthcare
Regulated, Risky, or Revolutionary? AI’s Role Across Drug Discovery, Devices, and Wellness
This panel will discuss regulatory issues, business plans, and risk-mitigation strategies for investors and companies as they scale and commercialize AI tools.

– Deeona Gaskin, Partner, Food, Drug and Medical Device and Former Associate Chief Counsel for Enforcement, FDA
– Scott Kaplan, Senior Vice President, Quality, Regulatory and Patient Safety, Baxter
– Michael Rohr, Partner, Emerging Companies and Venture Capital
– Luis Vilarin, Vice President, Legal, Flagship Pioneer
Life Sciences Dealmaking in 2026: Where Capital and Collaboration Converge
This panel will discuss the evolving biotech transaction landscape, from venture financings to strategic alliances.
– Jason Kropp, Partner, Emerging Companies and Venture Capital
– Irina Margine, Sector Lead, Biotech Private Investments, Wellington Management
– Rosemary Reilly, Partner, Emerging Companies and Venture Capital
FIRESIDE CHAT
“Navigating the New Environment in DC: New Advocacy Options for Life Sciences Companies at FDA and Beyond”
A conversation with former Senior White House Official Trent Morse and Becky Wood, co-leader of Sidley’s FDA Practice and former FDA Chief Counsel.
Agenda
Registration: 1:30 p.m. ET
Program: 2:00 p.m. ET
Reception: 5:00 p.m. ET
Who Should Attend?
Executives, Investors, General Counsel, and Company Counsel

By invitation only. Space is limited. For more information, contact bosevents@sidley.com.

Hong Kong Life Sciences Roundtable
2026-06-24 14:30 - 18:00 (Asia/Hong_Kong) | Sidley Hong Kong Office, 39/F, Two Int’l Finance Centre, Central, Hong Kong, Hong Kong
Join us for an exclusive discussion on cross-border business development strategies for life sciences companies, unlocking critical market opportunities at every stage.

The event will discuss:
– Industry Outlook for Innovation, Regulation and Commercialization
– BIOSECURE Act Coalition: A Coordinated Effort to Influence How the Act is Implemented
– Cross-border Licensing Outlook and Commercialization Strategies for Innovation
– M&A for Biotech and Medtech Assets from the Hong Kong Listing Rules Perspectives
– Evolving Post-listing Financing Landscape and Optimizing Capital Raising Strategies
– Navigating the Highs and Lows in Life Sciences

This is an invitation only event. For more information, please contact asiaevents@sidley.com.

Bay Area Life Sciences Roundtable
2026-07-22 13:00 - 16:30 (America/Los_Angeles) | SFMOMA, 147 Minna St. Floor 5, San Francisco, CA, 94103, United States
Please join Sidley at SFMOMA for our annual Bay Area Life Sciences Roundtable, an afternoon of thoughtful and engaging discussions addressing cutting-edge trends and hot topics.

By Invitation Only. Space is limited. For questions, please contact sfevents@sidley.com.
Who may be interested in attending:
Executives, Directors, Investors, and In-House Counsel
CLE credit for this program is pending.

Swiss MedTech 2026 MedTech in Recalibration: Staying Ahead in Regulation, AI, and the Deal Landscape
2026-08-25 14:00 - 18:00 (Europe/Zurich) | Casino Bern, Casinoplatz 1, 3011, Bern, Switzerland
Sidley, ISS AG, and Swiss Medtech invite you to our annual Swiss MedTech afternoon, bringing together regulators, industry leaders, legal thought leaders, and scientific advisers to exchange insights on the evolving MedTech landscape.

RSVP here.

2026 is a pivotal year for Swiss and European MedTech. MDR and IVDR revisions are progressing, while the AI Act timeline for medical devices has been adjusted under the Digital Omnibus agreement.
At the same time, EU simplification initiatives are reshaping sustainability, digitalization, and reporting obligations.
Manufacturers also face growing geopolitical and economic pressures, including supply chain disruption, trade uncertainty, and rising costs.
In Switzerland, proposed Swissmedic supervisory fees, the TPITO revision and the rollout of swissdamed are adding further complexity, while increased M&A activity continues to reshape the sector.
Key highlights on the agenda include:
The European Regulatory Reset: Navigating MDR/IVDR Revision and Omnibus
What is changing, what is at stake, and how Swiss manufacturers should prepare for the next phase of the European regulatory framework.
Operational Resilience in a Volatile Market Environment
How trade tensions, supply chain dependencies, sustainability and PFAS-related requirements, and regulatory change are influencing manufacturing, sourcing, and long-term decisions.
Switzerland: Additional Economic Pressure on Manufacturers
Swissmedic supervisory fees, swissdamed implementation, proposed TPITO revisions, and evolving anti-corruption expectations — and what they mean for Swiss manufacturers.
AI Act: From Uncertainty to Implementation
The revised timeline for AI-enabled medical devices and the practical implications for MDSW strategy, data governance, and compliance planning.
Strategic Deals in MedTech
How AI, market access, supply chain resilience, and regulatory complexity are reshaping acquisition strategies, valuations, and investment decisions.
Who should attend?
Executives, investors, in-house counsel, and regulatory managers interested in and/or facing regulatory issues in Switzerland.
For more information or questions, please contact Geneva Events.

Sidley Healthcare Investment Conference 2026
2026-09-22 | The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, UK, The Francis Crick Institute, 1 Midland Road, London, NW1 1AT, United Kingdom
As dealmaking and investment continue to shape the future of life sciences and healthcare, Sidley will convene senior leaders from pharma, biotech, healthcare, private equity, and venture capital to explore the forces defining the year ahead.

RSVP here.
Join Sidley and industry decision-makers from around the world for this one-day, in-person program in London, with a virtual attendance and networking option available for those joining from outside the UK.
Expect a day of sharp insights, dynamic discussion, and valuable networking as we explore how the continued convergence of innovation and capital is driving positive patient outcomes and investment returns.
View the Sidley Healthcare Investment Conference 2025 highlights.
